← Back to Clinical Trials
Recruiting NCT06145841

NCT06145841 Metagenomic Next-Generation Sequencing Guides Anti-Infection Strategies

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06145841
Status Recruiting
Phase
Sponsor Guangzhou 8th People's Hospital
Condition AIDS
Study Type OBSERVATIONAL
Enrollment 400 participants
Start Date 2023-10-23
Primary Completion 2026-10-23

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type OBSERVATIONAL
Interventions
Pathogen metagenomic next-generation sequencing

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 400 participants in total. It began in 2023-10-23 with a primary completion date of 2026-10-23.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to observe the effectiveness of clinical application in guiding anti-infection treatments in AIDS patients with severe pneumonia and/or sepsis using Metagenomic Next-Generation Sequencing-based technology in the real world

Eligibility Criteria

Inclusion Criteria: 1. Confirmed HIV infection; 2. Progression to AIDS stage: CD4+ count \<200 cells/ul and/or occurrence of AIDS opportunistic infections; 3. Age between 18 and 65 years; 4. Meeting the diagnosis of severe pneumonia or septic shock: 1. The criteria for severe pneumonia diagnosis refer to the 2021 ATS (American Thoracic Society) and IDSA (Infectious Diseases Society of America) guidelines for the treatment of community-acquired pneumonia; 2. The criteria for septic shock refer to the Chinese Society of Critical Care Medicine's "Chinese Guidelines for the Emergency Treatment of Sepsis/Septic Shock (2018). Exclusion Criteria: 1. Coexisting central nervous system lesions, severe liver disease, or cirrhosis; 2. Concurrent AIDS-related or unrelated tumors; 3. Women who are pregnant or breastfeeding; 4. Severe underlying diseases of the heart, lungs, liver, kidneys, etc.; 5. Alcohol abuse or drug use; 6. The researcher believes that the overall condition of the subject affects the evaluation and completion of the trial.

Frequently Asked Questions

Who can join the NCT06145841 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying AIDS. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06145841 currently recruiting?

Yes, NCT06145841 is actively recruiting participants. Visit ClinicalTrials.gov or contact Guangzhou 8th People's Hospital to inquire about joining.

Where is the NCT06145841 trial being conducted?

This trial is being conducted at Guangzhou, China.

Who is sponsoring the NCT06145841 clinical trial?

NCT06145841 is sponsored by Guangzhou 8th People's Hospital. The trial plans to enroll 400 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology